Publications

Skip to content

New and Noteworthy

Explore our latest insights, research, and stories

How real-world data from over 420,000 patients reveals treatment gaps in prostate and bladder cancer care

Real-world evidence
Event recap
Artificial intelligence
Blog

From data to decisions: What “regulatory-grade” real-world evidence actually requires
- Real-world evidence
- Event recap
Flatiron Health attends the 2026 American Society of Genitourinary Cancers Symposium to answer oncology's most critical questions
Flatiron launches first-of-its-kind AI-powered global prostate cancer datasets

Featured topics

Real-world evidence
Point of care
Flatiron stories
Clinical decision support
Video
Machine learning
Press releases
Post marketing requirements
HTA and market access
Health equity
Case study

All the latest

Topics

Artificial intelligence

Clinical decision support

Inclusion

Data management

Drug Discovery

Flatiron stories

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Patient identification

Point of Care

Post marketing requirements

Practice management

Precision medicine

Prospective study

Protocol optimization

Real-World Evidence

Regulatory

Site identification

Technology & Engineering

Treatment patterns

Trial design

Unmet need

Value-based care

Content type

Article

Press releases

Case study

Publications

Customer interviews

Event recap

Video

Podcast

Showing 9 of 0 results

How real-world data from over 420,000 patients reveals treatment gaps in prostate and bladder cancer care
From data to decisions: What “regulatory-grade” real-world evidence actually requires
- Real-world evidence
- Event recap
Impact of real-world response to first-line immunotherapy and chemotherapy on subsequent treatment outcomes in patients with advanced or metastatic non-small cell lung cancer
JCO Cancer Clinical Informatics
Flatiron Health attends the 2026 American Society of Genitourinary Cancers Symposium to answer oncology's most critical questions
Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)
ASCO GU
Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations
ASCO GU
Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with locally advanced/metastatic urothelial cancer
ASCO GU
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
ASCO GU
Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment
ASCO GU

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2026